MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Company”), a medical stage pharmaceutical firm dedicated to expanding healthy and balanced life expectancy, today introduced that the first individual has been signed up in the Company’s Stage 2 medical trial of lead candidate MYMD-1, a dental immune regulatory authority medicine, as a treatment for postponing aging and increasing healthy life-span.
The key endpoint for the Stage 2 double-blind, placebo-controlled professional trial is to achieve a decrease in the distributing levels of (TNF-α), tumor necrosis factor receptor I (TNFRI) as well as IL-6. TNF-α and IL-6 are the proteins in the body that trigger inflammation and help activate the procedure of aging. The additional actions of the trial will certainly be the safety and security, tolerability, as well as pharmacokinetics in this population of individuals.
” In a Stage 1 medical trial of MYMD-1, we showed the medicine’s statistically considerable efficiency in decreasing degrees of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually accepted TNF-α reduction as the main endpoint for our Phase 2 research, which our team believe settings us well for a successful Phase 2 outcome,” claimed Chris Chapman, M.D., President, Director as well as Chief Medical Policeman of MyMD. “The initiation of person registration in this study advances our goal to slow the aging procedure, stop loss of muscle cells in aging, limitation frailty, as well as prolong healthy and balanced life expectancy.”
MyMD has actually mentioned that there are no FDA-approved medicines for treating aging conditions and expanding healthy and balanced life expectancy humans, a market expected to be at the very least $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are the most prescribed medicines by profits, an international market of about $40 billion annually,2 and also, according to Nature Aging journal,3 a stagnation in aging that would raise life expectancy by one year deserves $38 trillion and also by one decade is worth $367 trillion.
In addition to aging, MYMD-1’s distinctive activity in regulating the immune system and also treating chronic inflammation is being created for the therapy of autoimmune condition, including rheumatoid joint inflammation (RA), several sclerosis (MS), diabetes, and also inflammatory digestive tract illness.
” We mean to start writing procedures for a Stage 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The rising occurrence of rheumatoid joint inflammation as well as various other autoimmune as well as inflammatory conditions are driving demand for TNF inhibitors like MYMD-1, and our team believe our by mouth administered drug with really low poisoning would be turbulent to the $60 billion market for RA if authorized by the FDA for this sign.”
Rheumatoid joint inflammation impacts approximately 40 million individuals around the world.4.
Originally created for autoimmune conditions, MYMD-1’s key function is to slow the aging procedure, prevent sarcopenia and also frailty, as well as extend healthy and balanced lifespan. Due to the fact that it can go across the blood-brain barrier and also get to the central nerves (CNS), MYMD-1 is additionally positioned to be a feasible treatment for brain-related disorders. Its device of action as well as efficacy in diseases including multiple sclerosis (MS) and thyroiditis have actually been studied through cooperations with several scholastic institutions. MYMD-1 is likewise revealing pledge in pre-clinical studies as a prospective treatment for article- COVID-19 problems and as an anti-fibrotic as well as anti-proliferation therapeutic.
MYMD-1 has shown efficiency in pre-clinical studies in managing the body immune system by performing as a discerning prevention of growth necrosis factor-alpha (TNF-α), a driver of persistent swelling. Unlike other treatments, MYMD-1 has been received these pre-clinical researches to uniquely obstruct TNF-α when it ends up being overactivated in autoimmune conditions and cytokine tornados, however not obstruct it from doing its typical work of being a very first -responder to any routine type of modest infection. MYMD-1’s simplicity of dental dosing is another differentiator compared to presently readily available TNF-α blockers, all of which call for delivery by injection or infusion. No accepted TNF prevention has actually ever been dosed by mouth. Additionally, the medicine is not immunosuppressive and has not been shown to cause the major side effects common with typical therapies that treat inflammation.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional stage pharmaceutical firm dedicated to extending healthy life-span, is concentrated on establishing 2 unique healing platforms that treat the sources of disease as opposed to only addressing the signs. MYMD-1 is a drug platform based upon a professional phase tiny particle that manages the body immune system to regulate TNF-α, which drives chronic swelling, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, rise longevity, and also treat autoimmune illness and COVID-19- connected depression. The Company’s second drug platform, Supera-CBD, is being created to treat persistent pain, dependency and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and also is being developed to deal with and also improve upon the swiftly growing CBD market, which includes both FDA accepted medicines as well as CBD products not currently managed as medicines. To learn more, see www.mymd.com.